MA34642B1 - Anticorps dirigé contre le tweak humain et leurs utilisations - Google Patents

Anticorps dirigé contre le tweak humain et leurs utilisations

Info

Publication number
MA34642B1
MA34642B1 MA35867A MA35867A MA34642B1 MA 34642 B1 MA34642 B1 MA 34642B1 MA 35867 A MA35867 A MA 35867A MA 35867 A MA35867 A MA 35867A MA 34642 B1 MA34642 B1 MA 34642B1
Authority
MA
Morocco
Prior art keywords
tweak
diseases
directed against
antibodies directed
against human
Prior art date
Application number
MA35867A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34642B1 publication Critical patent/MA34642B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)

Abstract

L'invention concerne un anticorps se liant à TWEAK, caractérisé par la liaison à TWEAK, caractérisé en ce qu'il comprend en tant que domaine variable de la chaîne lourde un CDR3H choisi dans le groupe consistant en SEQ ID NO: 8, 16 ou 24, qui est utile pour le traitement du cancer ou de maladies auto-immunes, de la polyarthrite rhumatoïde, de la polyarthrite psoriasique, de maladies musculaires, par exemple la dystrophie musculaire, de la sclérose en plaque, de maladies rénales chroniques, de maladies osseuses, par exemple la dégénérescence osseuse dans des myélomes multiples, du lupus érythémateux disséminé, de la néphropathie lupique et de lésions vasculaires.
MA35867A 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations MA34642B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10186536 2010-10-05
PCT/EP2011/067070 WO2012045671A1 (fr) 2010-10-05 2011-09-30 Anticorps dirigé contre le tweak humain et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34642B1 true MA34642B1 (fr) 2013-11-02

Family

ID=43086385

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35867A MA34642B1 (fr) 2010-10-05 2013-05-03 Anticorps dirigé contre le tweak humain et leurs utilisations

Country Status (21)

Country Link
US (1) US9187564B2 (fr)
EP (1) EP2625200A1 (fr)
JP (1) JP5941049B2 (fr)
KR (1) KR101584416B1 (fr)
CN (1) CN103154029B (fr)
AR (1) AR083336A1 (fr)
AU (1) AU2011311673B2 (fr)
BR (1) BR112013007293A2 (fr)
CA (1) CA2809632A1 (fr)
CL (1) CL2013000901A1 (fr)
CR (1) CR20130108A (fr)
EA (1) EA201300418A1 (fr)
EC (1) ECSP13012542A (fr)
MA (1) MA34642B1 (fr)
MX (1) MX343114B (fr)
NZ (1) NZ607588A (fr)
PE (1) PE20131411A1 (fr)
PH (1) PH12013500506A1 (fr)
SG (1) SG188605A1 (fr)
TW (1) TWI482630B (fr)
WO (1) WO2012045671A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007163A (es) * 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
WO2006089095A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de troubles neurologiques
CA2607697C (fr) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
WO2006138219A2 (fr) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Procedes d'evaluation de patients
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
WO2013150043A1 (fr) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Anticorps bispécifiques dirigés contre tweak humain et l'il17 humaine, et leurs utilisations
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
WO2015051234A2 (fr) * 2013-10-04 2015-04-09 Biogen Idec Ma Inc. Antagonistes de tweak pour traiter la néphropathie lupique et l'atrophie musculaire
EP3174897B1 (fr) * 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Anticorps multi-spécifiques
MY204672A (en) 2018-10-31 2024-09-09 Astellas Pharma Inc Anti-human fn14 antibody
CN112180100A (zh) * 2020-09-27 2021-01-05 西安交通大学 Tweak作为鉴别不同类型银屑病的分子标志物的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
JP3537535B2 (ja) 1994-07-14 2004-06-14 株式会社中埜酢店 免疫グロブリンｇ結合糖鎖構造に基づく臨床検査方法
JP2000514641A (ja) 1995-11-03 2000-11-07 ザ マウント シナイ メディカル センター 異種移植拒絶を低減するための方法および組成物
CZ297387B6 (cs) 1996-08-07 2006-11-15 Biogen Idec Ma Inc. Sekvence DNA kódující ligand príbuzný TNF, polypeptid a zpusob jeho prípravy, protilátka reaktivní s polypeptidem a farmaceutická kompozice
AU5874798A (en) 1997-01-31 1998-08-25 Biovation Limited Vaccination methods and molecules
EP0983303B1 (fr) 1997-05-21 2006-03-08 Biovation Limited Procede de production de proteines non immunogenes
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
MXPA01007163A (es) 1999-01-15 2002-03-27 Biogen Inc Antagonistas de tweak y de receptores de tweak y su uso para tratar trastornos inmunologicos.
MX352180B (es) 2002-04-09 2017-11-13 Biogen Ma Inc El uso de antagonistas de tweak para el tratamiento de condiciones relacionadas con tweak.
JP2008501621A (ja) 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
CA2534639C (fr) 2003-07-31 2013-07-30 Immunomedics, Inc. Anticorps anti-cd19
AR045614A1 (es) 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
EP1811838A4 (fr) 2004-11-08 2009-07-22 Univ Maryland Tweak comme cible therapeutique permettant de traiter les maladies du systeme nerveux central associees a un oedeme cerebral et a une mort cellulaire
HUE025945T2 (en) 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
WO2006089095A2 (fr) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Traitement de troubles neurologiques
US20090068102A1 (en) 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
EP1853312B1 (fr) * 2005-03-07 2014-12-10 Genentech, Inc. Methodes et compositions de modulation de l'activite de tweak et de fn14
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2607697C (fr) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Traitement et evaluation des troubles inflammatoires
WO2006130429A2 (fr) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Traitement du cancer
MEP35408A (en) 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
JP2008546647A (ja) 2005-06-08 2008-12-25 デューク ユニバーシティ 移植のための抗−ｃｄ１９抗体治療
CA2611814A1 (fr) 2005-06-20 2007-01-04 Medarex, Inc. Anticorps cd19 et utilisations
EP1937306B1 (fr) 2005-08-19 2016-02-17 Janssen Biotech, Inc. Préparations d'anticorps résistants à la protéolyse
PE20071101A1 (es) 2005-08-31 2007-12-21 Amgen Inc Polipeptidos y anticuerpos
DE102005060813A1 (de) 2005-12-20 2007-06-28 Rheinisch-Westfälische Technische Hochschule Aachen Selektive Markierung der Glykane von Antikörpern mit modifizierten Nukleotidzuckern als Substrate von rekombinanten Galactosyltransferasen
EP1878747A1 (fr) 2006-07-11 2008-01-16 greenovation Biotech GmbH Anticorps glyco-modifiés
AU2007317755A1 (en) 2006-10-27 2008-05-15 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
MX343114B (es) 2016-10-25
BR112013007293A2 (pt) 2016-06-14
CR20130108A (es) 2013-04-29
HK1186195A1 (zh) 2014-03-07
CL2013000901A1 (es) 2013-11-29
MX2013003592A (es) 2013-05-31
JP5941049B2 (ja) 2016-06-29
CN103154029A (zh) 2013-06-12
JP2013543383A (ja) 2013-12-05
TWI482630B (zh) 2015-05-01
EA201300418A1 (ru) 2013-09-30
SG188605A1 (en) 2013-04-30
KR101584416B1 (ko) 2016-01-13
CA2809632A1 (fr) 2012-04-12
CN103154029B (zh) 2015-11-25
NZ607588A (en) 2014-02-28
KR20130062369A (ko) 2013-06-12
US9187564B2 (en) 2015-11-17
EP2625200A1 (fr) 2013-08-14
AU2011311673B2 (en) 2015-09-17
US20120121583A1 (en) 2012-05-17
WO2012045671A1 (fr) 2012-04-12
PH12013500506A1 (en) 2017-08-23
PE20131411A1 (es) 2013-12-16
AR083336A1 (es) 2013-02-21
AU2011311673A1 (en) 2013-03-14
TW201219054A (en) 2012-05-16
ECSP13012542A (es) 2013-06-28

Similar Documents

Publication Publication Date Title
MA34642B1 (fr) Anticorps dirigé contre le tweak humain et leurs utilisations
MA38382A1 (fr) Anticorps qui se lie a la sous-unite p19 de l'interleukine-23 humaine comprenant une chaine legere et une chaine lourde, utilise pour traiter ou prevenir par ex. La sclerose en plaques, la polyarthrite rhumatoïde, le psoriasis, le cancer et les maladies inflammatoires de l'intestin
MX2009006891A (es) Anticuerpos cd44.
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
MA35345B1 (fr) Proteines de liaisons a un antigene ayant une liaison accrue a fcrn
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MX2010010387A (es) Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
WO2009048537A3 (fr) Anticorps humanisé
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
MX2009009194A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
WO2007062245A3 (fr) Anticorps monoclonal humain cd134 (ox40) et procedes de fabrication et d'utilisation de celui-ci
MA31308B1 (fr) Anticorps antisclerostine.
MA30318B1 (fr) Composes de sulfonamide de pyrimidinyle inhibant l'adhesion leucocytaire mediee par vla-4
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
EA201000424A1 (ru) Антитела к il-23
MA28982B1 (fr) Anticorps antagonistes de il-17
EP3530736A3 (fr) Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
TW200740844A (en) Novel MAdCAM antibodies
MA33387B1 (fr) Polypeptides et procede de traitement
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha